Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Growing topline compensating biosimilar erosion Roche CHFM 30,713 +5% at CER +64 -987 +627 + 1,576 +392 -90 HY 2021 Diagnostics Diagnostics Pharma base COVID-19 underlying business sales business Ronapreve AHR sales erosion1 Fx HY 2021 and HY 2022 values in reported CHFm, variances in CERm; 1AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion (2.5bn for FY 2022) 32,295 HY 2022 53

View entire presentation